Neuroprotection by neuropeptide Y in cell and animal models of Parkinson's disease

Neurobiology of Aging

Volumn 33, Issue 9, 2012, Pages 2125-2137

  Decressac, Mickael ^a   Pain, Stéphanie ^a   Chabeauti, Pierre Yves ^a   Frangeul, Laura ^a   Thiriet, Nathalie ^a   Herzog, Herbert ^b   Vergote, Jackie ^c   Chalon, Sylvie ^c   Jaber, Mohamed ^a   Gaillard, Afsaneh ^a  

^a UNIVERSITÉ DE POITIERS   (France)

^b ST VINCENT S HOSPITAL   (Australia)

^c UNIVERSITÉ DE TOURS   (France)

Author keywords

Neuropeptide Y; Neuroprotection; Parkinson's disease

Indexed keywords

3,4 DIHYDROXYPHENYLACETIC ACID; BRAIN DERIVED NEUROTROPHIC FACTOR; DOPAMINE TRANSPORTER; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; NEUROPEPTIDE Y; PROTEIN KINASE B; TYROSINE 3 MONOOXYGENASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN DEGENERATION; CELL SURVIVAL; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; DRUG EFFECT; DRUG MECHANISM; ENZYME ACTIVATION; FEMALE; HUMAN; HUMAN CELL; MALE; MOUSE; NERVE STIMULATION; NEUROBLASTOMA CELL; NEUROPROTECTION; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; RAT; SUBSTANTIA NIGRA PARS COMPACTA; TRANSGENIC MOUSE;

ADRENERGIC AGENTS; ANALYSIS OF VARIANCE; ANIMALS; ANIMALS, NEWBORN; ARGININE; AUTORADIOGRAPHY; CELL LINE, TUMOR; CELL SURVIVAL; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DISEASE MODELS, ANIMAL; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; DOPAMINERGIC NEURONS; ENZYME INHIBITORS; FEMALE; FUNCTIONAL LATERALITY; HUMANS; MALE; MAP KINASE SIGNALING SYSTEM; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; NEUROBLASTOMA; NEURODEGENERATIVE DISEASES; NEUROPEPTIDE Y; NEUROPROTECTIVE AGENTS; NORTROPANES; OLIGOPEPTIDES; OXIDOPAMINE; PARKINSON DISEASE; PROTEIN BINDING; RATS; RATS, WISTAR; RECEPTORS, NEUROPEPTIDE Y; SUBSTANTIA NIGRA; TYROSINE 3-MONOOXYGENASE;

EID: 84863435661     PISSN: 01974580     EISSN: 15581497     Source Type: Journal    
DOI: 10.1016/j.neurobiolaging.2011.06.018     Document Type: Article

References (49)

1. Adrian T.E., Allen J.M., Bloom S.R., Ghatei M.A., Rossor M.N., Roberts G.W., Crow T.J., Tatemoto K., Polak J.M. Neuropeptide Y distribution in human brain. Nature 1983, 306:584-586.
2. Allen Y.S., Adrian T.E., Allen J.M., Tatemoto K., Crow T.J., Bloom S.R., Polak J.M. Neuropeptide Y distribution in the rat brain. Science 1983, 221:877-879.
3. Alvarez-Fischer D., Henze C., Strenzke C., Westrich J., Ferger B., Höglinger G.U., Oertel W.H., Hartmann A. Characterization of the striatal 6-OHDA model of Parkinson's disease in wild type and alpha-synuclein-deleted mice. Exp. Neurol 2008, 210:182-193.
4. Alvaro A.R., Martins J., Costa A.C., Fernandes E., Carvalho F., Ambrósio A.F., Cavadas C. Neuropeptide Y protects retinal neural cells against cell death induced by ecstasy. Neuroscience 2008, 152:97-105.
5. Balasubramaniam A.A. Neuropeptide Y family of hormones: receptor subtypes and antagonists. Peptides 1997, 18:445-457.
6. Bensadoun J.C., Déglon N., Tseng J.L., Ridet J.L., Zurn A.D., Aebischer P. Lentiviral vectors as a gene delivery system in the mouse midbrain: cellular and behavioral improvements in a 6-OHDA model of Parkinson's disease using GDNF. Exp. Neurol 2000, 164:15-24.
7. Bezard E., Jaber M., Gonon F., Boireau A., Bloch B., Gross C.E. Adaptive changes in the nigrostriatal pathway in response to increased 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurodegeneration in the mouse. Eur. J. Neurosci 2000, 12:2892-2900.
8. Cannizzaro C., Tel B.C., Rose S., Zeng B.Y., Jenner P. Increased neuropeptide Y mRNA expression in striatum in Parkinson's disease. Brain Res. Mol. Brain Res 2003, 110:169-176.
9. Cavanaugh J.E., Jaumotte J.D., Lakoski J.M., Zigmond M.J. Neuroprotective role of ERK1/2 and ERK5 in a dopaminergic cell line under basal conditions and in response to oxidative stress. J. Neurosci. Res 2006, 84:1367-1375.
10. Chalon S., Garreau L., Emond P., Zimmer L., Vilar M.P., Besnard J.C., Guilloteau D. Pharmacological characterization of (E)-N-(3-iodoprop-2-enyl)-2beta-carbomethoxy-3beta-(4'-methylphenyl)n ortropane as a selective and potent inhibitor of the neuronal dopamine transporter. J. Pharmacol. Exp. Ther 1999, 291:648-654.
11. Chen S.H., Cheung R.T. Neuropeptide Y-Y1 receptor agonist worsens while antagonist improves survival of cultured Y1-expressing neuronal cells following oxygen and glucose deprivation. J. Biomed. Sci 2004, 11:781-788.
12. Decressac M., Wright B., Tyers P., Gaillard A., Barker R.A. Neuropeptide Y modifies the disease course in the R6/2 transgenic model of Huntington's disease. Exp. Neurol 2010, 226:24-32.
13. Gaillard A., Decressac M., Frappé I., Fernagut P.O., Prestoz L., Besnard S., Jaber M. Anatomical and functional reconstruction of the nigrostriatal pathway by intranigral transplants. Neurobiol. Dis 2009, 35:477-488.
14. Gaillard A., Jaber M. Rewiring the brain with cell transplantation in Parkinson's disease. Trends Neurosci 2011, 34:124-133.
15. Guo S., Bezard E., Zhao B. Protective effect of green tea polyphenols on the SH-SY5Y cells against 6-OHDA induced apoptosis through ROS-NO pathway. Free Radic. Biol. Med 2005, 39:682-695.
16. Kastin A.J., Akerstrom V. Nonsaturable entry of neuropeptide Y into brain. Am. J. Physiol 1999, 276:E479-E482.
17. Kerkerian L., Bosler O., Pelletier G., Nieoullon A. Striatal neuropeptide Y neurones are under the influence of the nigrostriatal dopaminergic pathway: immunohistochemical evidence. Neurosci. Lett 1986, 66:106-112.
18. Kerkerian L., Salin P., Nieoullon A. Pharmacological characterization of dopaminergic influence on expression of neuropeptide Y immunoreactivity by rat striatal neurons. Neuroscience 1988, 26:809-817.
19. Kirik D., Georgievska B., Björklund A. Localized striatal delivery of glial cell line-derived neurotrophic factor as a treatment for Parkinson disease. Nat. Neurosci 2004, 7:105-110.
20. Lang A.E., Lozano A.M. Parkinson's disease. First of two parts. N Engl J. Med 1998, 339:1044-1053.
21. Lin E., Cavanaugh J.E., Leak R.K., Perez R.G., Zigmond M.J. Rapid activation of ERK by 6-hydroxydopamine promotes survival of dopaminergic cells. J. Neurosci. Res 2008, 86:108-117.
22. Lindgren N., Leak R.K., Carlson K.M., Smith A.D., Zigmond M.J. Activation of the extracellular signal-regulated kinases 1 and 2 by glial cell line-derived neurotrophic factor and its relation to neuroprotection in a mouse model of Parkinson's disease. J. Neurosci. Res 2008, 86:2039-2049.
23. Meshul C.K., Emre N., Nakamura C.M., Allen C., Donohue M.K., Buckman J.F. Time-dependent changes in striatal glutamate synapses following a 6-hydroxydopamine lesion. Neuroscience 1999, 88:1-16.
24. Noe' F., Nissinen J., Pitkänen A., Gobbi M., Sperk G., During M., Vezzani A. Gene therapy in epilepsy: the focus on NPY. Peptides 2007, 28:377-383.
25. Obuchowicz E., Antkiewicz-Michaluk L., Romańska I., Herman Z.S. Increased striatal neuropeptide Y immunoreactivity and its modulation by deprenyl, clonidine and L-dopa in MPTP-treated mice. J. Neural Transm 2003, 110:1375-1391.
26. Paxinos G., Franklin K.B.J. The Mouse Brain in Stereotaxic Coordinates 2001, Academic Press, San Diego, CA. second ed.
27. Paxinos G., Watson C. The Rat Brain in Stereotaxic Coordinates 1986, Academic Press, San Diego, CA. second ed.
28. Pedrazzini T., Seydoux J., Künstner P., Aubert J.F., Grouzmann E., Beermann F., Brunner H.R. Cardiovascular response, feeding behavior and locomotor activity in mice lacking the NPY Y1 receptor. Nat. Med 1998, 4:722-726.
29. Ries V., Henchcliffe C., Kareva T., Rzhetskaya M., Bland R., During M.J., Kholodilov N., Burke R.E. Oncoprotein Akt/PKB induces trophic effects in murine models of Parkinson's disease. Proc. Natl. Acad. Sci. U. S. A. 2006, 103:18757-18762.
30. Rose J.B., Crews L., Rockenstein E., Adame A., Mante M., Hersh L.B., Gage F.H., Spencer B., Potkar R., Marr R.A., Masliah E. Neuropeptide Y fragments derived from neprilysin processing are neuroprotective in a transgenic model of Alzheimer's disease. J. Neurosci 2009, 29:1115-1125.
31. Sainsbury A., Schwarzer C., Couzens M., Fetissov S., Furtinger S., Jenkins A., Cox H.M., Sperk G., Hökfelt T., Herzog H. Important role of hypothalamic Y2 receptors in body weight regulation revealed in conditional knockout mice. Proc. Natl. Acad. Sci. U. S. A. 2002, 99:8938-8943.
32. Shaw J.L., Gackenheimer S.L., Gehlert D.R. Functional autoradiography of neuropeptide Y Y1 and Y2 receptor subtypes in rat brain using agonist stimulated [35S]GTPgammaS binding. J. Chem. Neuroanat 2003, 26:179-193.
33. Shimohama S., Sawada H., Kitamura Y., Taniguchi T. Disease model: Parkinson's disease. Trends Mol. Med 2003, 9:360-365.
34. Silva A.P., Carvalho A.P., Carvalho C.M., Malva J.O. Functional interaction between neuropeptide Y receptors and modulation of calcium channels in the rat hippocampus. Neuropharmacology 2003, 44:282-292.
35. Silva A.P., Pinheiro P.S., Carvalho A.P., Carvalho C.M., Jakobsen B., Zimmer J., Malva J.O. Activation of neuropeptide Y receptors is neuroprotective against excitotoxicity in organotypic hippocampal slice cultures. FASEB J 2003, 17:1118-1120.
36. Silva A.P., Xapelli S., Grouzmann E., Cavadas C. The putative neuroprotective role of neuropeptide Y in the central nervous system. Curr. Drug Targets. CNS Neurol. Disord 2005, 4:331-347.
37. Silva A.P., Xapelli S., Pinheiro P.S., Ferreira R., Lourenço J., Cristóvão A., Grouzmann E., Cavadas C., Oliveira C.R., Malva J.O. Up-regulation of neuropeptide Y levels and modulation of glutamate release through neuropeptide Y receptors in the hippocampus of kainate-induced epileptic rats. J. Neurochem 2005, 93:163-170.
38. Smiałowska M., Domin H., Zieba B., Koúniewska E., Michalik R., Piotrowski P., Kajta M. Neuroprotective effects of neuropeptide Y-Y2 and Y5 receptor agonists in vitro and in vivo. Neuropeptides 2009, 43:235-249.
39. Stanić D., Brumovsky P., Fetissov S., Shuster S., Herzog H., Hökfelt T. Characterization of neuropeptide Y2 receptor protein expression in the mouse brain. I. Distribution in cell bodies and nerve terminals. J. Comp. Neurol 2006, 499:357-390.
40. Sun M., Kong L., Wang X., Lu X.G., Gao Q., Geller A.I. Comparison of the capability of GDNF, BDNF, or both, to protect nigrostriatal neurons in a rat model of Parkinson's disease. Brain Res 2005, 1052:119-129.
41. Thiriet N., Deng X., Solinas M., Ladenheim B., Curtis W., Goldberg S.R., Palmiter R.D., Cadet J.L. Neuropeptide Y protects against methamphetamine-induced neuronal apoptosis in the mouse striatum. J. Neurosci 2005, 25:5273-5279.
42. Timmons S., Coakley M.F., Moloney A.M., O'Neill C. Akt signal transduction dysfunction in Parkinson's disease. Neurosci. Lett 2009, 467:30-35.
43. Ungerstedt U., Arbuthnott G.W. Quantitative recording of rotational behavior in rats after 6-hydroxy-dopamine lesions of the nigrostriatal dopamine system. Brain Res 1970, 24:485-493.
44. Vezzani A., Sperk G., Colmers W.F. Neuropeptide Y: emerging evidence for a functional role in seizure modulation. Trends Neurosci 1999, 22:25-30.
45. Weng Z., Signore A.P., Gao Y., Wang S., Zhang F., Hastings T., Yin X.M., Chen J. Leptin protects against 6-hydroxydopamine-induced dopaminergic cell death via mitogen-activated protein kinase signaling. J. Biol. Chem 2007, 282:34479-34491.
46. West M.J., Slomianka L., Gundersen H.J. Unbiased stereological estimation of the total number of neurons in thesubdivisions of the rat hippocampus using the optical fractionator. Anat. Rec 1991, 231:482-497.
47. Wettstein J.G., Earley B., Junien J.L. Central nervous system pharmacology of neuropeptide Y. Pharmacol. Ther 1995, 65:397-414.
48. Xapelli S., Bernardino L., Ferreira R., Grade S., Silva A.P., Salgado J.R., Cavadas C., Grouzmann E., Poulsen F.R., Jakobsen B., Oliveira C.R., Zimmer J., Malva J.O. Interaction between neuropeptide Y (NPY) and brain-derived neurotrophic factor in NPY-mediated neuroprotection against excitotoxicity: a role for microglia. Eur. J. Neurosci 2008, 27:2089-2102.
49. Yurek D.M., Fletcher-Turner A. Differential expression of GDNF, BDNF, and NT-3 in the aging nigrostriatal system following a neurotoxic lesion. Brain Res 2001, 891:228-235.